Valley National Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.05M | Sell |
8,238
-144
| -2% | -$18K | 0.14% | 134 |
|
|
2025
Q4 | $1.02M | Buy |
8,382
+1,034
| +14% | +$119K | 0.14% | 133 |
|
|
2025
Q3 | $736K | Sell |
7,348
-1,721
| -19% | -$155K | 0.11% | 145 |
|
|
2025
Q2 | $752K | Sell |
9,069
-6,294
| -41% | -$502K | 0.12% | 144 |
|
|
2025
Q1 | $1.25M | Sell |
15,363
-1,225
| -7% | -$109K | 0.22% | 111 |
|
|
2024
Q4 | $1.49M | Sell |
16,588
-3,313
| -17% | -$321K | 0.27% | 99 |
|
|
2024
Q3 | $1.97M | Sell |
19,901
-3,598
| -15% | -$354K | 0.36% | 67 |
|
|
2024
Q2 | $2.18M | Buy |
23,499
+2,427
| +12% | +$218K | 0.32% | 70 |
|
|
2024
Q1 | $2M | Buy |
21,072
+15,426
| +273% | +$1.43M | 0.3% | 69 |
|
|
2023
Q4 | $504K | Buy |
5,646
+1,327
| +31% | +$98.5K | 0.08% | 161 |
|
|
2023
Q3 | $315K | Buy |
4,319
+1,729
| +67% | +$138K | 0.06% | 204 |
|
|
2023
Q2 | $216K | Sell |
2,590
-438
| -14% | -$36.6K | 0.04% | 234 |
|
|
2023
Q1 | $246K | Hold |
3,028
| – | – | 0.04% | 225 |
|
|
2022
Q4 | $255K | Buy |
3,028
+938
| +45% | +$75.9K | 0.05% | 222 |
|
|
2022
Q3 | $169K | Sell |
2,090
-1,409
| -40% | -$119K | 0.04% | 255 |
|
|
2022
Q2 | $292K | Hold |
3,499
| – | – | 0.06% | 193 |
|
|
2022
Q1 | $315K | Buy |
3,499
+76
| +2% | +$7.02K | 0.06% | 189 |
|
|
2021
Q4 | $383K | Sell |
3,423
-94
| -3% | -$11.3K | 0.07% | 180 |
|
|
2021
Q3 | $442K | Sell |
3,517
-9
| -0.3% | -$1.16K | 0.08% | 166 |
|
|
2021
Q2 | $477K | Buy |
3,526
+6
| +0.2% | +$789 | 0.09% | 155 |
|
|
2021
Q1 | $478K | Hold |
3,520
| – | – | 0.09% | 151 |
|
|
2020
Q4 | $496K | Hold |
3,520
| – | – | 0.1% | 133 |
|
|
2020
Q3 | $392K | Sell |
3,520
-259
| -7% | -$29K | 0.09% | 139 |
|
|
2020
Q2 | $423K | Sell |
3,779
-440
| -10% | -$43.3K | 0.1% | 122 |
|
|
2020
Q1 | $327K | Sell |
4,219
-757
| -15% | -$67K | 0.09% | 134 |
|
|
2019
Q4 | $473K | Buy |
4,976
+516
| +12% | +$44.6K | 0.12% | 127 |
|
|
2019
Q3 | $340K | Hold |
4,460
| – | – | 0.09% | 142 |
|
|
2019
Q2 | $391K | Sell |
4,460
-252
| -5% | -$21.5K | 0.11% | 131 |
|
|
2019
Q1 | $427K | Buy |
4,712
+209
| +5% | +$17.8K | 0.12% | 122 |
|
|
2018
Q4 | $323K | Sell |
4,503
-191
| -4% | -$15.4K | 0.1% | 134 |
|
|
2018
Q3 | $450K | Sell |
4,694
-1
| -0% | -$97 | 0.16% | 120 |
|
|
2018
Q2 | $447K | Buy |
4,695
+194
| +4% | +$17.8K | 0.17% | 113 |
|
|
2018
Q1 | $395K | Buy |
4,501
+429
| +11% | +$39.2K | 0.15% | 119 |
|
|
2017
Q4 | $346K | Hold |
4,072
| – | – | 0.12% | 124 |
|
|
2017
Q3 | $353K | Buy |
4,072
+780
| +24% | +$62.5K | 0.12% | 116 |
|
|
2017
Q2 | $254K | Sell |
3,292
-474
| -13% | -$33.6K | 0.09% | 131 |
|
|
2017
Q1 | $261K | Sell |
3,766
-48
| -1% | -$3.22K | 0.1% | 123 |
|
|
2016
Q4 | $226K | Buy |
3,814
+1,783
| +88% | +$110K | 0.1% | 136 |
|
|
2016
Q3 | $135K | Buy |
2,031
+1,120
| +123% | +$69.3K | 0.07% | 152 |
|
|
2016
Q2 | $49K | Hold |
911
| – | – | 0.03% | 236 |
|
|
2016
Q1 | $47K | Buy |
911
+334
| +58% | +$17.3K | 0.03% | 236 |
|
|
2015
Q4 | $41K | Sell |
577
-145
| -20% | -$9.89K | 0.02% | 234 |
|
|
2015
Q3 | $45K | Sell |
722
-1
| -0.1% | -$79 | 0.03% | 233 |
|
|
2015
Q2 | $61K | Sell |
723
-711
| -50% | -$55.3K | 0.03% | 223 |
|
|
2015
Q1 | $108K | Buy |
1,434
+534
| +59% | +$37.3K | 0.06% | 164 |
|
|
2014
Q4 | $39K | Buy |
+900
| New | +$51.3K | 0.03% | 180 |
|
Other funds holding XBI
Valley National Advisers's XBI Position: Q1 2026 in Review
Valley National Advisers reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.7% in Q1 2026, selling an estimated $18K and leaving 8,238 shares worth $1.05M. The position accounts for 0.14% of the portfolio, ranked #134.
Valley National Advisers first reported a position in XBI in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.18M in Q2 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Valley National Advisers held 8,238 shares of State Street SPDR S&P Biotech ETF worth $1.05M as of Q1 2026.
- Valley National Advisers sold 144 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $18K.
- State Street SPDR S&P Biotech ETF made up 0.14% of Valley National Advisers's portfolio in Q1 2026, its #134 holding.
- Valley National Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q4 2014 and has held it in 46 quarters since.
- Valley National Advisers's State Street SPDR S&P Biotech ETF position peaked at $2.18M in Q2 2024.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.